Brief: Zealand Pharma Announces Positive Phase 1A Topline Results With Kv1.3 Channel Blocker Zp9830
18/02/2026 06:36
Feb 18 (Reuters) - Zealand Pharma A/S ZELA.CO: ANNOUNCES POSITIVE PHASE 1A TOPLINE RESULTS WITH KV1.3 CHANNEL BLOCKER ZP9830 ZP9830 WAS WELL TOLERATED IN THIS SINGLE ASCENDING DOSE TRIAL, WITH NO DOSE-LIMITING SAFETY FINDINGS OR OTHER SAFETY CONCERNS OBSERVED Source text: ID:nGNX3XqDNn Further company coverage: ZELA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)